Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of HBM9036 (HL036) eye drops versus placebo in moderate to severe dry eye disease in China
CTR20202142Phase 3Active
- Sponsor
- Harbour BioMed
- Start
- Mar 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tanfanercept in dry eye syndrome (DED), sponsored by Harbour BioMed. Started Mar 2021; status: active.
02
Drugs
tanfanercept
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on CTR20202142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202142.